TiredTara

Another Long C🫩vid / Post-Vaccination trial just got announced today, and while it finally targets the real underlying driver, it still exposes the massive blind spot in how pharma designs these studies Invivyd and Mount Sinai’s SPEAR Study Group launched FLINTLOCK, a Phase 2 trial using a high-dose monoclonal antibody (VYD2311) specifically for Long COVID and Post-Vaccination Syndrome. 👌The Good: It’s a major validation of what we've been saying all along—this isn't an "unexplained nervous system glitch" or lingering phantom. It's driven by the persistent presence of SARS-CoV-2 Spike protein. They are using a massive "brute force" strategy (10x the standard dose) via IV and monthly injections to flood the system and neutralize circulating Spike. 🪤The Catch: Look closely at how they’re measuring whether it "works": functional mobility tests, symptom surveys, and blood serum levels through Day 90. 👉 Zero tissue surveillance. No gut mucosal biopsies, no microvascular tissue sampling, and no bone marrow tracking. 👉 They aren't even requiring participants to have a confirmed baseline tissue antigen test to enroll. My Take: Flooding the bloodstream with high-dose monoclonal antibodies might act as a massive sponge by mopping up circulating Spike protein, clearing vascular endotheliitis, and giving people real symptomatic relief while the drug is in their system. That may be a win for quality of life temporarily. But without tissue biopsies, a 90-day survey-based trial won't prove whether the hidden reservoirs in our marrow and gut are actually eradicated, or if the fire reignites once the drug clears. I suspect the latter. It hasn't so far. It’s encouraging to see researchers force pharma to target viral persistence, but until medicine starts measuring tissue mechanics directly, they're still only looking at the surface. We need biomarkers for tissue marrow and platelet persistence. That is the only way we will actually get somewhere with substance. #LongCovid